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PHeart Rhythm Disorders
Activating Autoantibodies to the Beta-1
Adrenergic and M2 Muscarinic Receptors Facilitate
Atrial Fibrillation in Patients With Graves’ Hyperthyroidism
Stavros Stavrakis, MD,*† Xichun Yu, MD,*†‡ Eugene Patterson, PHD,†§ Shijun Huang, MD,*†‡
Sean R. Hamlett, MD,*‡ Laura Chalmers, MD,*‡ Reji Pappy, MD,*
Madeleine W. Cunningham, PHD, Syed A. Morshed, PHD,¶ Terry F. Davies, MD,¶
Ralph Lazzara, MD,*† David C. Kem, MD*†‡
Oklahoma City, Oklahoma; and New York, New York
Objectives We studied activating autoantibodies to beta-1 adrenergic receptors (AA1AR) and activating autoantibodies to
M2 muscarinic receptors (AAM2R) in the genesis of atrial fibrillation (AF) in Graves’ hyperthyroidism.
Background Atrial fibrillation frequently complicates hyperthyroidism. Both AA1AR and AAM2R have been described in
some patients with dilated cardiomyopathy and AF. We hypothesized that their copresence would facilitate AF in
autoimmune Graves’ hyperthyroidism.
Methods Immunoglobulin G purified from 38 patients with Graves’ hyperthyroidism with AF (n  17) or sinus rhythm (n 
21) and 10 healthy control subjects was tested for its effects on isolated canine Purkinje fiber contractility with
and without atropine and nadolol. Immunoglobulin G electrophysiologic effects were studied using intracellular
recordings from isolated canine pulmonary veins. Potential cross-reactivity of AA1AR and AAM2R with stimulat-
ing thyrotropin receptor (TSHR) antibodies was evaluated before and after adsorption to Chinese hamster ovary
cells expressing human TSHRs using flow cytometry and enzyme-linked immunosorbent assays.
Results The frequency of AA1AR and/or AAM2R differed significantly between patients with AF and sinus rhythm
(AA1AR  94% vs. 38%, p  0.001; AAM2R  88% vs. 19%, p  0.001; and AA1ARAAM2R  82% vs.
10%, p  0.001). The copresence of AA1AR and AAM2R was the strongest predictor of AF (odds ratio: 33.61,
95% confidence interval: 1.17 to 964.11, p  0.04). Immunoglobulin G from autoantibody-positive patients in-
duced hyperpolarization, decreased action potential duration, enhanced early afterdepolarization formation, and
facilitated triggered firing in pulmonary veins by local autonomic nerve stimulation. Immunoadsorption studies
showed that AA1AR and AAM2R were immunologically distinct from TSHR antibodies.
Conclusions When present in patients with Graves’ hyperthyroidism, AA1AR and AAM2R facilitate development of AF.
(J Am Coll Cardiol 2009;54:1309–16) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.07.015m
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Myperthyroidism has been associated with atrial tachyarrhyth-
ias (1–3) and with sustained atrial fibrillation (AF) occurring
n 20% to 30% of patients even after return to the euthyroid
tate (1,2). The pathogenesis of AF in these patients is
ostulated to result from shortening of the action potential
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raves’ disease is one of the most common causes of hyperthy-
oidism (6). The prevalence of AF in patients with Graves’ disease,
s in all other forms of hyperthyroidism, increases with age (1,2,6).
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receptor (TSHR) (6,7). Activat-
ing autoantibodies to the beta-1
adrenergic receptors (AA1AR)
and the M2 muscarinic receptors
(AAM2R) variably occur in pa-
tients with several cardiomyopa-
thies and in a subset of patients
with AF (8–13). The AA1AR
show positive inotropic and chro-
notropic effects (14,15), whereas
AAM2R have negative chrono-
tropic effects (13) and decrease
the action potential duration in
isolated cardiomyocytes (10). The
presence of AAM2R was associ-
ated with the occurrence of AF in
patients with idiopathic dilated
cardiomyopathy (13). Combined
sympathetic and parasympathetic
stimulation has been shown to
generate early afterdepolarizations
and rapid triggered firing in the
pulmonary veins, which in turn
induces AF (16,17). Given the
synergistic role of sympathetic and
parasympathetic activity for initia-
tion and/or maintenance of AF
(18,19), we hypothesized: 1) pa-
ients with Graves’ hyperthyroidism develop significant
iters of AA1AR and AAM2R; and 2) these autoantibod-
es facilitate development of AF.
ethods
tudy patients. Thirty-eight patients with Graves’ hyper-
hyroidism with AF (n 17) or sinus rhythm (n 21) were
ncluded in the study through referral and were seen by an
ndocrinologist and cardiologist. The diagnosis of Graves’
yperthyroidism was based on markedly suppressed serum
hyrotropin concentrations, elevated serum free thyroxine
nd triiodothyronine concentrations, and evidence of diffuse
oiter with increased 24-h radionuclide uptake (6). Mea-
urement of TSHR antibodies was generally obtained but
ot required unless there was ambiguity in the diagnosis. All
atients were seen during a 2-year period. The AF was
onfirmed by a 12-lead electrocardiogram. Echocardio-
rams were performed in all but 4 patients (1 with AF and
with sinus rhythm). Serum was obtained from each
atient and 10 voluntary healthy donors (mean age 29.5 
.2 years). This study was approved by the University of
klahoma Health Sciences Center Institutional Review
oard, and all subjects provided written informed consent.
urification of immunoglobulin (Ig) G antibody. The IgG
as purified using the NAb Protein A/G Spin Kit (Pierce,
Abbreviations
and Acronyms
AA1AR  activating
autoantibodies to beta-1
adrenergic receptor
AAM2R  activating
autoantibodies to M2
muscarinic receptor
AF  atrial fibrillation
CHO-TSHR  Chinese
hamster ovary cells
expressing full-length
thyrotropin receptor
CI  confidence interval
DT  deceleration time of
mitral E flow velocity
E  early diastolic velocity
of mitral inflow
E/E=  ratio between the
early diastolic velocity of
mitral inflow and that of
mitral annulus
ELISA  enzyme-linked
immunosorbent assay
Ig  immunoglobulin
M2R  M2 muscarinic
receptor
TSHR  thyrotropin
receptorockford, Illinois), according to the manufacturer’s protocol. Vontractility bioassay. Free-running canine Purkinje fi-
ers (5 to 7 mm) were transferred to a 36°C  0.1°C
erfusion chamber mounted on the stage of an inverted
icroscope (Olympus America Inc., Melville, New York)
20). The fibers were perfused with normal Tyrode solution
in mmol/l: NaCl 145, KCl 4.5, CaCl2 1.8, MgCl2 1,
aH2PO4 1, glucose 11, HEPES 10, pH 7.36) at 36 
.1°C and paced with a 4-ms duration constant current
ulse at 2 Hz via extracellular platinum electrodes. Isometric
ontractions were recorded before, during steady state, and
fter the washout using a video edge detector (Model
ED-205, Crescent Electronics, Sandy, Utah). After
chieving stable contractile responses over 3 to 5 min, IgG
quivalent to a 1:100 serum dilution from a patient or
ontrol subject was administered for a 5-min interval. With
ubsequent 5-min periods, IgG plus atropine (100 nmol/l)
r nadolol (100 nmol/l) was assayed to determine the effect
ttributable to the AA1AR or AAM2R components of
gG, respectively. Isoproterenol (10 nmol/l) served as a
ositive control. The IgG from healthy donors served as
egative control subjects. Contractility was calculated as the
ean of 15 consecutive contraction cycles after a stable
aseline or response was elicited and analyzed offline using
Clamp 9.2 (Axon Instruments, Foster City, California).
ny response that was significantly different from the
aseline with a p  0.05 was considered to be positive.
ncreased contractility over baseline with IgG plus atropine
epresented the AA1AR effect. The change in IgG effect
n contractility with and without atropine was a surrogate
arker of the AAM2R inhibitory effect. The intra-assay
nd interassay coefficients of variation were 6.6% (n  24)
nd 8.6% (n  38), respectively.
lectrical recordings. Isolated canine pulmonary vein
reparations (16) were pinned endocardial side up and
uperfused with oxygenated Tyrode solution at 36°C (20
l/min). A bipolar electrode recording (0.10 mm diameter
eflon-coated silver wires, 1 mm apart) was obtained,
ltered at 10 to 10,000 Hz, and recorded on a Gould
indowGraf recorder (Gould Inc., Valley View, Ohio). An
ntracellular recording was obtained using a glass microelec-
rode with an intracellular resistance of 10 to 30 M (Duo
73 electrometer, World Precision Instruments, Sarasota,
lorida) and was maintained for the duration of evaluation
f a single IgG sample. The preparation was paced at 2 to
 diastolic threshold using 4-ms-duration stimuli from a
rass model S88 stimulator (Quincy, Massachusetts) at 1
z. Intracellular recordings were performed before and after
utonomic nerve stimulation from the immediate vicinity of
he stimulating electrodes (within 2 to 3 mm) and before
nd after superfusion of the preparation with IgG (0.15
g/ml). Local autonomic nerve stimulation was accom-
lished using 300-ms-duration high-frequency (100 Hz)
rains of 0.05-ms-duration square-wave stimuli introduced
t 10 to 150 V in 20-V steps from a Grass stimulator.
oltage was maintained at 50% of the threshold voltage
r
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September 29, 2009:1309–16 Antiautonomic Receptor Antibodies in Graves’ AFequired to excite local myocardium when introduced as
.05-ms-duration stimuli during a 2-Hz pacing train.
etection of TSHR antibodies by flow cytometry. Puri-
ed IgG samples were diluted (1:200) with isotonic
hosphate-buffered saline containing 4% bovine serum albu-
in and 0.01% sodium azide and incubated with Chinese
amster ovary cells expressing full-length human thyrotropin
eceptor (CHO-TSHR cells) (21). Antihuman IgG (HL)
onjugated with fluorescein isothiocyanate (BD Bioscience
harmingen, San Diego, California) was the secondary anti-
ody. The mean fluorescent intensity was measured by flow
ytometry (BD Bioscience Pharmingen). A human monoclo-
al antibody (M22) to the TSHR that stimulates cyclic
denosine monophosphate in CHO-TSHR cells confirmed
SHR-specific binding.
dsorption study. The CHO-TSHR cells were maintained
n Ham’s F12 medium supplemented with 10% fetal bovine
erum (Mediatech, Manassas, Virginia), 100 U/ml penicillin,
nd 100 U/ml streptomycin (Invitrogen, Grand Island, New
ork). Fully confluent cells were detached by phosphate-
uffered saline containing 1 mM ethylenediaminetetraacetic
cid and 1 mM ethyleneglycotetraacetic acid. Counted (1 
06) cells were incubated with 100 l of diluted (1:200)
urified IgG for 30 min with mild rocking at room tempera-
ure. The IgG-adsorbed samples were collected by centrifuga-
ion. Flow cytometry was performed using pre- and post-
dsorption samples in parallel. A reduction in mean fluorescent
ntensity of 25% indicated significant adsorption. All exper-
ments were performed twice. Pre- and post-adsorbed serum
amples were analyzed in duplicate by enzyme-linked immu-
osorbent assay (ELISA) for antibody titers to the 1AR and
2R using whole receptors expressed in membranes
PerkinElmer, Waltham, Massachusetts) (20).
tatistical analysis. Data are expressed as mean  SD.
ontractility values were normalized to their baseline val-
es. Comparison between 2 groups was performed by using
he unpaired or paired Student t test for quantitative
ariables, as applicable, and the Fisher exact test for dichot-
mous variables. The McNemar test was used for the
atched analysis. Linear correlation was performed to
xamine the strength of the linear relationship between the
rue AAM2R effect and its surrogate. Repeated-measures
nalysis of variance was used to determine differences within
group with drug treatment. Logistic regression analysis
as used to assess predictors of AF. Those variables with p
alues 0.10 by univariate analysis were included in the
ultivariate logistic regression analysis model, and the
espective odds ratios (ORs) were calculated. All analyses
ere 2-tailed. Statistical significance was set at p  0.05.
esults
atient characteristics. Seventeen patients had AF and 21
ad sinus rhythm. The clinical, echocardiographic, and
iochemical characteristics of the patients are summarized
n Table 1. Patients with AF were older than patients with pinus rhythm (60.9  12.7 years vs. 45.7  13.1 years, p 
.001). Otherwise, no difference was noted for the percent-
ge of male sex, presence of hypertension, diabetes mellitus,
oronary artery disease, and congestive heart failure between
he 2 groups. Echocardiographic indexes, including left ven-
ricular ejection fraction, left atrial diameter, early diastolic
elocity of mitral inflow (E), deceleration time of mitral E flow
elocity (DT), and the ratio between the early diastolic velocity
f mitral inflow and that of mitral annulus (E/E=) did not differ
ignificantly between the 2 groups. Serum thyrotropin and free
hyroxine concentrations were similar in the 2 groups.
ontractility bioassay. Twenty-four (63%) and 19 (50%) of
he 38 IgG samples showed AA1AR and AAM2R, respec-
ively. In 16 (42%) IgG samples, AA1AR and AAM2R
oexisted. None of 10 control IgG samples showed either
utoantibody group. The -adrenergic receptor agonist isopro-
erenol (10 nmol/l) increased contractility 48.4  4.9% over
aseline (p  0.001). The mean IgG agonist effect (percent
ver baseline) from the 24 AA1AR-positive patients in the
resence of M2R blockade was 25.6  9.6% (p  0.001 vs.
ontrol subjects). The absolute mean inhibitory AAM2R effect
percent change over baseline) in the 19 AAM2R-positive
atients was 28.1  16.6% (p  0.001 vs. control subjects)
Fig. 1A). The change in IgG effect on contractility with and
ithout atropine correlated strongly with the IgG effect in the
resence of nadolol (R2  0.67, p  0.001, n  12),
upporting the use of the atropine-induced change as a
urrogate for the AAM2R effect. During each assay, the effect
f combined AR and M2R blockade with nadolol and
tropine led to a return of the IgG response to baseline. These
ata, not shown, provide additional evidence against the
opresence of additional autoantibodies causing Purkinje con-
ractile response.
The frequency of autoantibody positivity differed signif-
cantly between the 2 groups (Fig. 1B). Sixteen of 17 (94%)
linical, Echocardiographic, andiochemical Characterist s of the PatientsTable 1 Clinical, Echo ardiographic, andBiochemical Characteristics of the Patients
Atrial
Fibrillation
(n  17)
Normal Sinus
Rhythm
(n  21) p Value
Age (yrs) 60.9 12.7 45.7 13.1 0.001*
Male (%) 47.1 42.9 1.00
Hypertension (%) 70.6 61.9 0.73
Diabetes mellitus (%) 35.3 23.8 0.49
Coronary artery disease (%) 17.6 9.5 0.64
Heart failure (%) 52.9 23.8 0.09
Ejection fraction (%) 51.6 16.1 52.4 16.2 0.88
Left atrium (mm) 42.3 7.8 38.3 7.6 0.15
E (m/s) 0.83 0.25 0.98 0.37 0.17
DT (ms) 245.2 72.2 242.4 77.9 0.90
E/E= 5.9 2.5 6.6 2.5 0.50
Serum thyrotropin (mU/l) 0.075 0.12 0.071 0.18 0.94
Serum free thyroxine (ng/dl) 2.35 1.3 3.08 2.3 0.22
T deceleration time of mitral E flow velocity; E early diastolic velocity of mitral inflow; E/E=
atio between the early diastolic velocity of mitral inflow (E) and that of mitral annulus (E=).atients with AF were positive for AA1AR, compared
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Antiautonomic Receptor Antibodies in Graves’ AF September 29, 2009:1309–16ith only 8 of 21 (38%) patients with sinus rhythm (p 
.001). Likewise, 15 (88%) patients with AF were positive
or AAM2R, compared with 4 (19%) patients with sinus
hythm (p  0.001). Both autoantibodies coexisted in 14
82%) patients with AF, compared with only 2 (10%)
atients with sinus rhythm (p  0.001).
lectrophysiologic effects of IgG. The electrophysiologic
ffects of IgG from 14 autoantibody-positive patients on
anine pulmonary vein sleeves are summarized in Table 2.
he IgG equivalent to a 1:100 serum dilution (0.15 mg/ml)
educed the resting membrane potential compared with
re-IgG values, increased the action potential amplitude,
nd decreased the action potential duration at 50% and 90%
Figure 1
Functional Effects of IgG
From Patients With Graves’ Disease and
Control Subjects on Purkinje Fiber Contractility
(A) The mean effect (percent over baseline) of activating autoantibodies to
beta-1 adrenergic receptor (AA1AR) from the 24 AA1AR-positive patients
(Graves’ AA1AR) and the absolute value of the mean inhibitory effect (percent
change over baseline) of activating autoantibodies to M2 muscarinic receptor
(AAM2R) in the 19 AAM2R-positive patients (Graves’ AAM2R) are compared
with control immunoglobulin (Ig)G. The antibody-negative Graves’ values were
not significantly different from the control subjects and therefore are not
shown. Isoproterenol (ISO) (10 nmol/l) served as a positive control. Both
AA1AR and AAM2R effects were significantly greater in patients than in con-
trol subjects. *p  0.001. (B) The percentages of autoantibody-positive
patients for AA1AR and AAM2R and their combination are shown. Autoanti-
bodies were significantly more frequent in patients with atrial fibrillation (AF)
compared with patients with normal sinus rhythm (NSR). *p  0.001.f repolarization (Fig. 2A). Pause-duration–dependent pro- oongation of the terminal action potential duration (action
otential duration at 90% of repolarization) was enhanced
fter a 20-beat pacing train at 6 Hz for pause durations of
50, 500, 1,000, 2,000, and 4,000 ms, respectively, in the
resence of IgG compared with control subjects (p  0.01
or each pause duration). With rapid pacing followed by a
rolonged pause, prolongation of the terminal phase of the
ction potential clearly assumes the form of an early after-
epolarization (Figs. 2B and 2C). Triggered firing with
ocal autonomic nerve stimulation was observed in 50% and
9% of the pulmonary sleeve preparations before and after
gG, respectively (p  NS). The IgG decreased the voltage
f the stimulus train needed to induce triggered firing,
ignificantly moving the stimulus voltage-response curve to
he left (EV50  70  2 V vs. 96  2 V after and before
gG, respectively, p  0.001) (Figs. 2D and 2E). Early
fterdepolarization formation and local autonomic nerve
timulation–induced triggered firing were blocked by ateno-
ol (32 nmol/l). Hyperpolarization, action potential short-
ning, and local autonomic nerve stimulation-induced trig-
ered firing were blocked by atropine (32 nmol/l).
eterminants of AF. Univariate analyses were performed
or 14 variables, listed in Table 3. The copresence of
A1AR and AAM2R, old age, heart failure, and in-
reased AA1AR (percent over baseline) and AAM2R
ffects (percent change over baseline) were significantly
elated to the presence of AF. Multivariate analysis showed
he copresence of AA1AR and AAM2R was the strongest
ndependent predictor of AF (OR: 33.61, 95% confidence
nterval [CI]: 1.17 to 964.11, p  0.04). Older age also
ndependently predicted the presence of AF (OR: 1.15, 95%
I: 1.02 to 1.31, p  0.03) (Table 3).
To minimize the impact of age, we examined a (within 5
ears) matched subgroup in our patient population. Ten
atients with AF and 10 patients with sinus rhythm (mean age
4.3  11.7 years vs. 53.0  12.6 years, p  0.81) could be
ompared. The copresence of AA1AR and AAM2R was
ignificantly more prevalent in patients with AF (90% vs. 0%,
 0.008).
A1AR andAAM2R are distinct fromTSHR antibodies.
e examined the potential binding of AA1AR and
AM2R to TSHR expressed in CHO cells. Diluted TSHR
lectrophysiologic Effects of IgG (n  14)Table 2 Electrophysiologic Effects of IgG (n  14)
Pre-IgG IgG (0.15 mg/ml)
Resting membrane potential (mV) 74.6 1.8 76.9 2.0*
Action potential amplitude (mV) 101.6 7.6 105.7 7.8*
Action potential duration at 50%
of repolarization (ms)
44.3 9.3 39.6 7.0*
Action potential duration at 90%
of repolarization (ms)
134.5 17.8 118.0 15.6*
Triggered firing (incidence) 50% 79%
Stim EV50 (V) 96 7 72 7†
p  0.01. †p  0.001 versus pre-IgG.
Ig immunoglobulin; Stim EV50 stimulation voltage that results in 50% of the total incidence
f triggered firing.
p
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September 29, 2009:1309–16 Antiautonomic Receptor Antibodies in Graves’ AFre-adsorbed sera from 5 subjects; 4 with elevated AA1AR
nd AAM2R and 1 ELISA-positive but nonactive normal
ontrol subject were incubated with fresh CHO-TSHR
Figure 2 Electrophysiologic Effects of IgG on Canine Pulmonary
(A) Action potentials are shown before (black) and after (red) IgG administration
action potential duration. (B) Enhanced early afterdepolarization formation produce
from pulmonary vein sleeves. Numbers represent action potential duration at 90%
potential duration (change in action potential duration at 90% of repolarization [	A
pared with control (n  14). *p  0.01 for each pause duration. (D) Electrical rec
(dark areas) show enhanced triggered firing after IgG versus before IgG administra
and 90% of repolarization. (E) Stimulus response curves (local autonomic nerve s
of triggered firing by IgG in canine pulmonary vein sleeves (significant movement o
duration at 50% of repolarization; RMP  resting membrane potential; other abbreells in triplicate. These cells were labeled with anti-IgG antibodies and subjected to flow cytometry. Nonadsorbed
era from the same patients were used for control subjects.
here was little binding and a 25% decrease in binding
Sleeves
strating hyperpolarization, increased action potential amplitude, and decreased
achycardia (6 Hz)-pause (2 sec) pacing is shown post-IgG in electrical recordings
olarization. (C) Pause-duration–dependent prolongation of the terminal action
with tachycardia (20-beat train at 6 Hz)-pause pacing is shown with IgG com-
s from pulmonary vein sleeves during local autonomic nerve stimulation
he numbers in the upper panel represent the action potential duration at 50%
ion) are shown before and after IgG administration, demonstrating enhancement
timulus voltage-response curve to the left) (n  14). APD50  action potential
s as in Figure 1.Vein
demon
d by t
of rep
PD90])
ording
tion. T
timulat
f the s
viationfter adsorption in the nonactive normal control subject and
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Antiautonomic Receptor Antibodies in Graves’ AF September 29, 2009:1309–16n the 2 non-Graves’ subjects that were negative for TSHR
ntibodies. By contrast, the 2 subjects with concurrent
SHR antibodies and activating autonomic receptor anti-
odies had significantly higher baseline binding and a
50% decrease in TSHR binding after adsorption (Fig. 3).
erial dilutions of the adsorbed and nonadsorbed sera were
xamined by ELISA using 1AR and M2R. There was no
nivariate and Multivariate Logistic Regression Analyses for 14 VaTable 3 Univariate and Multivariate Logistic Regression Analys
Variable
Univaria
Odds Ratio 95%
Copresence of AA1AR/AAM2R 44.33 6.51–30
Age (yrs) 1.10 1.03–1.1
Male sex 1.19 0.33–4.2
Hypertension 1.48 0.38–5.7
Diabetes mellitus 1.75 0.43–7.1
Coronary artery disease 2.01 0.30–13
Congestive heart failure 3.60 0.90–14
Ejection fraction (%) 1.00 0.96–1.0
Left atrium diameter (mm) 1.09 0.98–1.2
E/E= 0.73 0.32–1.6
Serum thyrotropin concentration (mU/l) 1.21 0.01–11
Serum free thyroxine concentration (ng/dl) 0.77 0.50–1.1
AA1AR effect 1.13 1.04–1.2
AAM2R effect 1.13 1.04–1.2
p  0.05. †p  0.10.
AA1AR activating autoantibodies to the 1-adrenergic receptor; AAM2R activating autoan
elocity of mitral inflow (E) and that of mitral annulus (E=).
Figure 3 Binding of Patient Sera to
CHO-TSHR Cells by Flow Cytometry
Fluorescence was measured after exposing these cells to 1:200 dilutions of puri-
fied IgG (before and after adsorption with TSHR) and fluorescein isothiocyanate-
labeled anti-human IgG. A 50% decrease supports a significant loss of binding
activity. Patients #1 and #2 had documented stimulating thyrotropin receptor
antibodies and coexisting activating autoantibodies to AA1AR and AAM2R.
Patients #3 and #4 were non-Graves’ patients harboring AA1AR and AAM2R.
Patient #5 was a control subject with nonactivating autoantibodies to 1AR
and M2R by ELISA. There were significant adsorbable antibodies to the TSHR
in the 2 Graves’ patients. The other 3 had either no or small amounts of
adsorbable activity. CHO-TSHR  Chinese hamster ovary cells expressing full-
length thyrotropin receptor; ELISA  enzyme-linked immunosorbent assay;
other abbreviations as inFigure 1.aignificant loss in the adsorbed IgG reactivity to the auto-
omic receptor targets (data not shown).
iscussion
raves’ disease and autoantibodies. A significant per-
entage of patients with Graves’ disease have activating
utoantibodies against the 1AR and M2R. This increased
requency was observed mainly in patients with AF. Auto-
ntibodies were present in some patients with sinus rhythm
ith a frequency greater than the 10% of a normal popula-
ion reported in a previous study (22). This correlates with
he fact that Graves’ disease is an autoimmune disease (6,7).
hyroid-specific autoantibodies, such as thyroid peroxidase
ntibodies and TSHR antibodies, are present in 75% and
0% to 95% of patients with Graves’ disease, respectively
6,23). The genetic, environmental, and endogenous factors
esponsible for the pathogenesis of Graves’ disease increase
he propensity of these patients to develop other autoanti-
odies (6).
raves’ hyperthyroidism and AF. In our study, traditional
isk factors including hypertension, heart failure, increased
eft atrial diameter, and increased left ventricular filling
ressures (as predicted by E/E= ratio) did not identify AF
isk in patients with Graves’ disease. Stimulation of atrial
2Rs facilitates initiation and maintenance of AF (18), and
AM2R facilitates AF in patients with dilated cardiomy-
pathy (13). Our results likewise indicate that AA1AR
nd AAM2R facilitate AF formation in Graves’ hyperthy-
oidism. Recent experimental findings describing rapid
riggered firing from the canine pulmonary veins (16–19,24)
rovide important insights into a possible mechanism for
hese observed arrhythmogenic effects of AAM2R and
A1AR in patients with Graves’ disease. Simultaneous
sr 14 Variables
Multivariate
p Value Odds Ratio 95% CI p Value
0.001* 33.61 1.17–964.11 0.04*
0.006* 1.15 1.02–1.31 0.03*
1.00
0.73
0.49
0.64
0.09† 0.84 0.05–15.40 0.91
0.92
0.13
0.49
0.94
0.23
0.002* 1.06 0.93–1.20 0.37
0.003* 1.07 0.94–1.22 0.31
s to the M2 muscarinic receptor; CI confidence interval; E/E= ratio between the early diastolicriablees fo
te
CI
1.90
8
9
9
8
.86
.37
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trium (18,19), local stimulation of both parasympathetic
nd sympathetic nerve endings (17), and simultaneous
dministration of acetylcholine plus norepinephrine (or
soproterenol) (16) all initiate rapid triggered firing from
anine pulmonary veins. The M2R activation (action po-
ential shortening) and 1AR activation (enhancement of
he calcium transient) are important and necessary compo-
ents for such triggered firing. Herein, we provide evidence
uggesting that both AAM2R and AA1AR exert sufficient
lectrophysiologic effects on pulmonary vein sleeve myocar-
ium to facilitate triggered firing. Shortening of the action
otential (AAM2R effect) and enhancement of tachycardia-
ause early afterdepolarization formation (AA1AR effect)
an generate an increased sodium–calcium exchange inward
urrent and early afterdepolarization formation (24). In the
oncentrations used within the isolated pulmonary vein
leeve, the antibodies induced early afterdepolarizations, but
ere not sufficient alone to provoke triggering. However,
he antibodies facilitated the generation of triggered firing
licited by local autonomic nerve stimulation. Although
xcess thyroid hormone per se can cause shortening of the
ction potential duration in atrial and pulmonary vein
yocytes (4,5), the effects of AA1AR and AAM2R
esulted from activation of their respective receptors because
heir effects could be blocked with the -blocker atenolol
nd M2R blocker atropine, respectively. Elimination of the
bserved electrophysiologic effects with -adrenergic and
2 muscarinic blockade suggests that it is unlikely that the
SHR autoantibodies directly caused these effects. Evi-
ence from 4 subjects suggests that the autoantibody effects
id not result from cross-reactivity of TSHR autoantibodies
ith the 1AR and M2R. These data from our ex vivo
xperiments are consistent with the concept that autoanti-
ody activation of both 1AR and M2R facilitates initiation
nd maintenance of AF in patients and is responsible in part
or the high incidence of AF in Graves’ hyperthyroidism.
Age was an independent predictor of AF in our patient
opulation, as in other studies (2,6). Autoantibody preva-
ence also increases with age in the normal population (22).
t is likely that age, activating autoantibodies, and thyroid
ormone act synergistically in this population.
tudy limitations. It is possible that age differences in the
F and non-AF groups in this observational cross-sectional
tudy might confound our data. Although not a case-control
tudy, in an age-matched subgroup of our patient popula-
ion the association between the copresence of AA1AR
nd AAM2R and AF remained highly statistically signifi-
ant. We did not use long-term monitoring to identify
atients in the non-AF group with unrecognized episodes
f AF. However, the high rates of AF in patients with
raves’ hyperthyroidism make the identification of a
ignificant number of such episodes unlikely. The results
f the multivariate analysis, although of interest, are
imited by the relatively small number of observations
ncluded in the model and should be interpreted withaution. Finally, although other autoantibodies directed
oward other receptors might exist, it is unlikely that they
xert a significant electrophysiologic action, because the
bserved electrophysiologic effects were blocked completely
ith atenolol and atropine.
onclusions
n patients with Graves’ hyperthyroidism, the copresence of
A1AR and AAM2R facilitates autonomic-induced rapid
riggered firing in pulmonary veins and is the strongest
ndependent predictor of AF. These unique activating
utoantibodies may play a role in the initiation and main-
enance of AF in this patient population.
eprint requests and correspondence: Dr. David C. Kem, Heart
hythm Institute, TCH6E103, 1200 Everett Drive, Oklahoma
ity, Oklahoma 73104. E-mail: david-kem@ouhsc.edu.
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Call for Papers Heart Failure
This is a call for submission of manuscripts dealing with Heart Failure.
In recognition of the increasing research advances and number of manuscripts submitted to
JACC on certain topics, we are planning to initiate a recurring program of expanded Focus
Issues devoted to selected topics. 
In rotation, the last issue of each month will be expanded to include additional papers related
either to Heart Failure or Heart Rhythm Disorders or Prevention/Outcomes. Thus,
four issues per year will highlight each of these subjects. The articles accepted for these issues
will be in addition to those submitted and published on these topics on a regular basis in our
regular issues. 
Heart Failure will be covered in the tenth expanded Focus Issue, and we are soliciting
manuscripts on this topic to be submitted by October 30, 2009 for publication on 
April 27, 2010. Please submit manuscripts online in the usual fashion at jaccsubmit.org.
Future solicitations will go out for papers in the areas of Heart Rhythm Disorders
and Prevention/Outcomes.
